WebDisclosure WebDisclosure
Basculer en Français
10083 Companies
206178 Keywords
136402 Articles
109307 Press releases
Headlines Articles Press releases GENSIGHT BIOLOGICS S.A. Remove
  1. Home
  2. Companies
  3. GENSIGHT BIOLOGICS S.A.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 05/07/2024 at 19:34, 1 year 10 months ago

    GenSight Biologics annonce la mise à disposition d'un prospectus pour la cotation de nouvelles actions sur Euronext Paris

    Euronext Paris Augmentation De Capital Thérapie Génique Prospectus Produits Biologiques GenSight
  • PRESS RELEASE

    published on 05/07/2024 at 19:29, 1 year 10 months ago

    Terms of availability of prospectuses

    GenSight Biologics announces availability of listing prospectus for new shares on Euronext Paris. The prospectus approved by AMF includes universal registration document, securities note, and summary
    Euronext Paris New Shares AMF Approval GenSight Biologics Listing Prospectus
    Logo of GENSIGHT BIOLOGICS S.A.
  • PRESS RELEASE

    published on 05/07/2024 at 19:29, 1 year 10 months ago

    Modalités de mise à disposition de prospectus

    GenSight Biologics annonce la mise à disposition d'un prospectus pour l'admission d'actions nouvelles sur Euronext Paris. La société spécialisée dans les thérapies géniques pour les maladies neurodégénératives informe sur le processus
    Euronext Paris Prospectus GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
    Logo of GENSIGHT BIOLOGICS S.A.
Previous page
1 ... 17 18
Accesswire
  • Published on 03/24/2026 at 18:55, 41 minutes ago

    Norse Gold Announces Closing of Private Placement Financing and Pending Reactivation on the TSX-V

  • Published on 03/24/2026 at 13:30, 6 hours 6 minutes ago

    GGL Resources Corp. Announces Closing of Earn-In Agreement with Nelson Resources Limited on Its Gold Point High-Grade Gold-Silver Project, Nevada

  • Published on 03/24/2026 at 13:30, 6 hours 6 minutes ago

    Innodata Announces Date of Annual Shareholder Meeting

  • Published on 03/24/2026 at 12:35, 7 hours 1 minute ago

    Silver X Acquires the High-Grade Pampas Gold-Silver Project, Expanding its Precious Metal Asset Base in Peru

  • Published on 03/24/2026 at 12:33, 7 hours 3 minutes ago

    Mako Mining Completes Acquisition of Mt. Hamilton in Nevada

View all ACCESSWIRE
EQS Group
  • Published on 03/24/2026 at 19:05, 31 minutes ago

    WBS Power Advances 3.2 GW Energy Infrastructure for Hyperscale Data Center Campus

  • Published on 03/24/2026 at 18:39, 56 minutes ago

    EQS-Adhoc: FORTEC Elektronik Aktiengesellschaft: Adjustment of the earnings forecast for the financial year 2025/2026

  • Published on 03/24/2026 at 18:00, 1 hour 36 minutes ago

    Cham Swiss Properties places bond of CHF 100 million

  • Published on 03/24/2026 at 17:50, 1 hour 46 minutes ago

    Annual General Meeting of Bellevue Group AG – all proposals approved

  • Published on 03/24/2026 at 17:44, 1 hour 52 minutes ago

    2025 Annual Report Publication

View all EQS
Les Echos
  • Published on 03/24/2026 at 18:21, 1 hour 15 minutes ago

    Résultats annuels 2025

  • Published on 03/24/2026 at 18:21, 1 hour 15 minutes ago

    2025 Annual results

  • Published on 03/24/2026 at 18:00, 1 hour 36 minutes ago

    i2S : Résultats annuels 2025

  • Published on 03/24/2026 at 17:46, 1 hour 50 minutes ago

    NRJ GROUP - Avis résultats annuels 2025

  • Published on 03/24/2026 at 17:46, 1 hour 50 minutes ago

    NRJ GROUP - Press release annual results 2025

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy